We presented the results on the 疗效 of RCI001 in 干眼症.
The drug demonstrated superior 疗效 in comparison with existing drugs, generating strong expectations for its potential success.
RudaCure is currently proceeding with GMP production of the drug and is targeting FDA 临床试验 entry in 2023.